Introduction
Endocarditis is a rare manifestation of systemic Candidiasis in premature infants who require intensive care and often need multiple antifungal agents. Endocarditis caused by Candida is associated with high mortality and morbidity. 1 Successful treatment often requires prolonged systemic antifungal therapy as well as surgical intervention. 2, 3 We report a case of fungal sepsis and endocarditis in a premature infant who was successfully treated with antifungal therapy in conjunction of thrombolytic therapy without need for surgical intervention.
Case report
This male infant was born at 27 weeks gestation with birth weight 1000 g to a 22 years old G 1 P 0 woman with suspected chorioamnionitis. He was delivered by cesarean section owing to complete breech presentation and Apgar scores were 3, 5 and 7 at 1, 5 and 10 min after delivery. He had respiratory distress syndrome and received mechanical ventilation for 3 days. Sepsis work-up was performed at birth and intravenous ampicillin and gentamicin were given for 72 h when blood cultures were considered negative. On day 12, he had increasing respiratory distress with multiple episodes of apnea, bradycardia and arterial desaturation. He was subsequently reintubated and a complete sepsis work-up was performed. The white blood cell count was elevated to 40 000 with an increased percentage of immature polymorphonuclear cells. Intravenous Vancomycin and Cefotaxime were administered for 7 days. Again, cultures were negative for bacteria and fungi. A Broviac central catheter was inserted on day of life 20 for poor venous access and administration of total parental nutrition. Another sepsis work-up occurred on day of life 27 and again administration of intravenous Vancomycin and Cefotaxime were started, but also Amphotericin B was begun. Blood and cerebrospinal fluid cultures grew Candida albicans so the Vancomycin and Cefotaxime were discontinued. Owing to worsening of respiratory symptoms, and positive repeat fungal cultures, intravenous Fluconazole was added. Antifungal agents were administered through the Broviac catheter. Repeated blood culture from the Broviac and a peripheral vein had no bacterial growth, but did grow Candida parapsilosis.
On day of life 50, the Broviac catheter was removed owing to local infection at the site of catheter insertion. Broviac catheter tip culture was negative. On day of life 56, an echocardiogram demonstrated a large vegetation on the tricuspid valve (see Figure 1 ). There were no other positive findings. Intravenous Amphotericin B was administered for a total of 6 weeks and fluconazole for 4 weeks. Follow-up blood cultures were negative.
However, the echocardiogram showed no change in the large tricuspid vegetation described as a pedunculated segment prolapsing into right ventricle during systole and reaching the right ventricular apex during diastole. Thrombolytic therapy with intravenous urokinase (4400 U/kg over 10 min followed by 4400 U/ kg/h) given continuously for 6 days. Following cessation of the urokinase, we used oral coumadin for 8 additional weeks. No bleeding problems occurred during urokinase therapy and head ultrasound remained normal. Subsequent serial echocardiograms showed resolution of the tricuspid valve vegetation.
Discussion
Premature infants treated with systemic antibiotics and requiring central venous catheters are at risk for development of fungal infections. 1 Systemic fungal infection is reported in very low birth weight infants less than 1500 g, as the third most frequent cause of late-onset sepsis and is associated with high mortality. 2 Fungal endocarditis is an uncommon complication of invasive candidial infection, but there is a reported increase in the incidence of such infection over the last 15 years. 4, 5 Therefore, early recognition of infection and therapy is imperative. Risk factors for fungal endocarditis in neonates include surgery for congenital heart disease, prolonged broad-spectrum antimicrobial therapy and prolonged parenteral nutrition through central venous catheter. 6 The last two risk factors were present in our patient.
Successful treatment of patients with endocarditis requires early recognition and aggressive management. Management of fungal endocarditis in premature infants is controversial. Use of prolonged antifungal therapy in conjunction with surgical removal of thrombus is shown to be an effective approach to the treatment of this complication. 1 Use of prolonged antifungal treatment alone is reported in few critically ill infants with fungal endocarditis. 6 Our patient manifested with persistence of intracardiac vegetation with negative fungal blood culture after antifungal therapy. Therefore, instead of subjecting this extremely premature infant with unstable pulmonary status for surgical treatment, we considered thrombolytic therapy with urokinase. Urokinase is a thrombolytic agent that acts directly on plasminogen and converts it to plasmin. Plasmin, in turn, digests fibrin. 7 Urokinase can indiscriminately dissolve not only pathologic thrombi but hemostatic clots as well and thereby may lead to serious hemorrhagic complication. Therefore, close monitoring of coagulation profile is extremely important. Risk of serious bleeding is shown to be 6% in studies utilizing urokinase therapy as treatment of pulmonary emboli in adults. 8 Our patient did not show or develop any adverse effects of the treatment and he had successful resolution of the intracardiac thrombus. This infant did not need a larger dose of urokinase than that required for adult patients, presumably owing to plasminogen deficiency in preterm and newborn infants. In recent years, use of low molecular mass Heparin (enoxaparin) and newer plasminogen activators including recombinant tissue-type plasminogen activator have shown promising results for alternative thrombolytic treatment in the neonatal period. 9, 10 Tridimensional echocardiography was extremely useful in serial evaluation of this intracardiac thrombus. This has also been shown in one previous case report. 11 In conclusion, thrombolytic therapy with urokinase in addition to systemic antifungal therapy proved to be an effective alternative to surgical thombectomy in this extremely preterm infant.
